The  Western Norway B-Vitamin Intervention Trial  (WENBIT)   Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovasc...
 
Folic Acid and Birth Defects <ul><li>About 2,500 neural tube defects per year in US </li></ul><ul><li>Occur at 26-28 days ...
Homocysteine <ul><li>Non-protein-forming, sulfur-containing amino acid </li></ul><ul><li>Formed exclusively by demethylati...
Hyperhomocystinemia <ul><li>Independent risk factor for atherosclerotic and thromboembolic disease </li></ul><ul><li>A 5 µ...
 
 
DESIGN <ul><li>In this randomized, double-blind, controlled trial, 3096 adult participants undergoing coronary angiography...
<ul><li>With use of a 2 x 2-factorial design, participants were randomly assigned to 1 of 4 groups  </li></ul><ul><li>rece...
BASELINE <ul><li>At baseline,  </li></ul><ul><li>59.3% had double- or triple-vessel disease, </li></ul><ul><li>83.7% had s...
The primary endpoint <ul><li>was a composite of all-cause death, nonfatal acute myocardial infarction, acute hospitalizati...
The trial was terminated early Median follow-up was 38.4 months  NORVIT, <ul><li>The trial was terminated early because of...
Mean plasma total homocysteine <ul><li>Mean plasma total homocysteine concentration was reduced by 30% after 1 year of tre...
Secondary endpoints <ul><li>were fatal and nonfatal acute myocardial infarction, acute hospitalization for angina pectoris...
WENBIT: Percentage of patients with cardiovascular events  Ebbing M et al.  JAMA  2008; 300:795-804. End point  Folic acid...
There were no differences in treatment response for the separate endpoints of death, total acute myocardial infarction, or...
<ul><li>The incidence of cancer was higher in the groups receiving folic acid; however, this finding was not statistically...
Upcoming SlideShare
Loading in …5
×

The Western Norway B Vitamin Intervention Trial (Wenbi Tb

757 views

Published on

B-vitamins intervention trial in stable CAD.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
757
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • The Western Norway B Vitamin Intervention Trial (Wenbi Tb

    1. 1. The Western Norway B-Vitamin Intervention Trial (WENBIT) Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography. A randomized controlled trial. JAMA . 2008;300:795-804.
    2. 3. Folic Acid and Birth Defects <ul><li>About 2,500 neural tube defects per year in US </li></ul><ul><li>Occur at 26-28 days post-conception </li></ul><ul><li>95% are spontaneous with no family history </li></ul><ul><li>1991 UK study showed 71% risk reduction in recurrences (4mg dose) </li></ul><ul><li>In 1999 (Nov NEJM) 85% reduction in risk for primary prevention (0.4mg dose) </li></ul><ul><li>Lifetime costs estimated to be $532.000 (2001, MOD) </li></ul>
    3. 4. Homocysteine <ul><li>Non-protein-forming, sulfur-containing amino acid </li></ul><ul><li>Formed exclusively by demethylation of methionine </li></ul><ul><li>Eliminated through one of two vitamin-dependent pathways, in addition to an alternate vitamin-independent pathway in liver </li></ul>
    4. 5. Hyperhomocystinemia <ul><li>Independent risk factor for atherosclerotic and thromboembolic disease </li></ul><ul><li>A 5 µM increase in serum level confers a 80% increased risk to women and a 60% increased risk to men for atherosclerotic vascular disease </li></ul><ul><li>In patients with coronary artery disease, serum homocysteine levels increase with the number of stenosed coronary vessels </li></ul><ul><li>Hyperhomocystinemia may reflect: </li></ul><ul><ul><li>Genetic defects </li></ul></ul><ul><ul><li>Folate (most common), pyridoxine (vitamin B 6 ), or cobalamin (vitamin B 12 ) deficiencies </li></ul></ul><ul><ul><li>Renal failure </li></ul></ul><ul><li>Serum levels of homocysteine may be lowered by supplementation with folate, vitamin B 6 , and vitamin B 12 </li></ul>
    5. 8. DESIGN <ul><li>In this randomized, double-blind, controlled trial, 3096 adult participants undergoing coronary angiography (20.5% women; mean age, 61.7 years) were randomly selected. </li></ul>
    6. 9. <ul><li>With use of a 2 x 2-factorial design, participants were randomly assigned to 1 of 4 groups </li></ul><ul><li>receiving daily oral treatment with folic acid (0.8 mg) plus vitamin B 12 (0.4 mg) and vitamin B 6 (40 mg; n = 772); </li></ul><ul><li>folic acid plus vitamin B 12 (n = 772); </li></ul><ul><li>vitamin B 6 alone (n = 772); </li></ul><ul><li>or placebo (n = 780). </li></ul>
    7. 10. BASELINE <ul><li>At baseline, </li></ul><ul><li>59.3% had double- or triple-vessel disease, </li></ul><ul><li>83.7% had stable angina pectoris, </li></ul><ul><li>and 14.9% had acute coronary syndromes. </li></ul>
    8. 11. The primary endpoint <ul><li>was a composite of all-cause death, nonfatal acute myocardial infarction, acute hospitalization for unstable angina pectoris, and nonfatal thromboembolic stroke. </li></ul>
    9. 12. The trial was terminated early Median follow-up was 38.4 months NORVIT, <ul><li>The trial was terminated early because of concern among participants due to preliminary results from a contemporaneous Norwegian trial suggesting adverse effects from the intervention. </li></ul>
    10. 13. Mean plasma total homocysteine <ul><li>Mean plasma total homocysteine concentration was reduced by 30% after 1 year of treatment in the groups receiving folic acid and vitamin B 12 ( P < 0.01). </li></ul>
    11. 14. Secondary endpoints <ul><li>were fatal and nonfatal acute myocardial infarction, acute hospitalization for angina pectoris, stable angina pectoris with angiographically verified progression, myocardial revascularization procedures, and fatal and nonfatal stroke </li></ul>
    12. 15. WENBIT: Percentage of patients with cardiovascular events Ebbing M et al. JAMA 2008; 300:795-804. End point Folic acid+B 12 +B 6 Folic acid+B 12 B 6 Placebo Primary end point 12.2 16.3 13.7 12.5 All-cause death 4.5 4.9 3.6 3.9 Acute MI 7.7 9.9 7.1 7.4 Unstable angina 2.9 3.8 3.1 3.5 Nonfatal thromboembolic stroke 1.4 2.2 2.6 2.4 Cancer 6.0 5.1 4.9 4.0
    13. 16. There were no differences in treatment response for the separate endpoints of death, total acute myocardial infarction, or unstable angina. The incidence of total stroke was lower in the groups receiving folic acid; however, this observation was not statistically significant. The incidence of acute hospitalization for angina pectoris was lower in the folic acid groups, reaching borderline statistical significance ( P = .05).
    14. 17. <ul><li>The incidence of cancer was higher in the groups receiving folic acid; however, this finding was not statistically significant. </li></ul><ul><li>There were no differences in the rates of adverse effects among the 4 intervention groups and no report of serious adverse events related to study medication. </li></ul>

    ×